Immune checkpoint blockade (ICB) therapy has been groundbreaking for HCC and works primarily by reinvigorating cytotoxic CD8+ T cells, which are repressed in the tumor microenvironment [15]. The gene discussed is CD8A; the disease is neoplasm.